GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Giant Biogene Holding Co Ltd (HKSE:02367) » Definitions » Total Receivables

Giant Biogene Holding Co (HKSE:02367) Total Receivables : HK$170 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Giant Biogene Holding Co Total Receivables?

Giant Biogene Holding Co's Total Receivables for the quarter that ended in Dec. 2023 was HK$170 Mil.


Giant Biogene Holding Co Total Receivables Historical Data

The historical data trend for Giant Biogene Holding Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Giant Biogene Holding Co Total Receivables Chart

Giant Biogene Holding Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
635.52 302.53 79.27 175.23 170.48

Giant Biogene Holding Co Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Total Receivables Get a 7-Day Free Trial 79.27 - 175.23 183.03 170.48

Giant Biogene Holding Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Giant Biogene Holding Co Total Receivables Related Terms

Thank you for viewing the detailed overview of Giant Biogene Holding Co's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Giant Biogene Holding Co (HKSE:02367) Business Description

Traded in Other Exchanges
N/A
Address
No. 1855, Shanglin Yuan 7th Road, Chang’an District, Shaanxi Province, Xi’an, CHN
Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.

Giant Biogene Holding Co (HKSE:02367) Headlines

No Headlines